TD Cowen raised the firm’s price target on Novavax (NVAX) to $9 from $8 and keeps a Hold rating on the shares. The firm updated its model following the Sanofi-led (SNY) H2H trial and draft 3rd party ICER review suggest Nuvaxovid may have differentiated tolerability profile compared to mRNA vaccines.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- TD Cowen’s Steve Scala Maintains Hold on NVAX, Nudges Price Target Up Amid Improved Tolerability Data but Limited Real‑World Effectiveness Evidence
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- NVAX Upcoming Earnings Report: What to Expect?
- Novavax: COMPARE Study Underscores Safety Edge of Nuvaxovid and Supports Upside from Royalties, Milestones, and Licensing
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says